The conference starts today and runs until Thursday.
Chief executive Dr Kunwar Shailubhai said: “I look forward to sharing our exciting story with conference attendees.
“With the release of our topline data from our COVID-19 trial, multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases in the longer-term, we are well positioned to achieve a series of important milestones in the months and quarters ahead.”
At the start of the month, the company released data from clinical trials of its nasally-delivered monoclonal antibody in people affected by coronavirus.
There was a significant improvement in lung function in the groups of patients receiving the drug, as well as major reductions in Interleukin-6 and c-reactive protein, which are both indicative of inflammation.
Tiziana’s Foralumab was administered on its own and with dexamethasone, a corticosteroid, and the results were compared with a control group.
The fully human anti-CD3 monoclonal antibody (mAB) proved to be safe in the group of 39 patients that were assessed by a team that included researchers from the prestigious Harvard Medical School.